A Phase 2 interventional study of ICP-332 Tablets and ICP-332 Tablets in Plaque Psoriasis, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 22 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.
Among the 206 studies in Psoriasis with a site in China, this one is the 89th largest by enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 42 in phase 2, and was the 176th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18+
Xijing Hospital · Sites in China
Ages 18–65
Zhejiang Wenda Pharma Technology LTD. · Sites in China
Ages 18–75 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 55 · Phase 3 60 · Phase 4 12
First in 2005; this study’s year is marked. 36 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 182 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 171 across the 182 interventional studies, 191 across the 24 observational. Of the 111 that completed or were terminated, 16 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 206 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing InnoCare Pharma Tech Co., Ltd., one of the names counted as InnoCare Pharma Limited. Under that name alone:
Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.
InnoCare Pharma Limited has 4 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
20 of the studies in Psoriasis with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07672561Phase 3Zhejiang Wenda Pharma Technology LTD.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis | 2026-11-30 |
| NCT07543224Phase 3Reistone Biopharma Company LimitedA Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaque Psoriasis. | 2027-01 |
| NCT07326813Phase 3InventisBio Co., LtdA Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis | 2027-07-12 |
| NCT07130604Phase 3InventisBio Co., LtdEvaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis | 2027-07-28 |
| NCT07724366Phase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | 2027-09 |
Add all 20 to your calendar (.ics) → With an account.
Among the 206 studies in Psoriasis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meet the following three criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ICP-332 Tablets
Drug: ICP-332 Tablets
Drug: ICP-332 Tablets
Other: ICP-332 Placebo Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 will be administered as tablet for 12 weeks
ICP-332 will be administered as tablet for 12 weeks
Placebo will be administered as tablet for 12 weeks
The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) at Week 12
Time frame: Day 1 to Day 85
Percentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)
Time frame: Day 1 to Day 85
Percentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)
Time frame: Day 1 to Day 85
Number of Participants With Adverse Events
Time frame: Day 1 to Day 113
The peak concentration (Cmax)
Time frame: Day 1, Day15, Day 29, Day 57
The time to peak (Tmax)
Time frame: Day 1, Day15, Day 29, Day 57
The half-life (t1/2)
Time frame: Day 1, Day15, Day 29, Day 57
The area under the blood concentration-time curve (AUC0-∞ and AUC0-t)
Time frame: Day 1, Day15, Day 29, Day 57
Ran from Dec 2025 to primary completion in Oct 2026, 10 months.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Oct 2026, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ICP-332
Beijing InnoCare Pharma Tech Co., Ltd. →